Atea Pharmaceuticals, Inc. Payments to Acquire Debt Securities, Available-for-sale
Atea Pharmaceuticals, Inc. (AVIR) reported Payments to Acquire Debt Securities, Available-for-sale of $108.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $33.81M, a 66.44% decline year-over-year.
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $74.55M, a 39.21% decline year-over-year.
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $43.79M, a 25.11% decline year-over-year.
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $14.78M, a 93.52% decline year-over-year.
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $281.94M, a 38.87% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $461.18M, a 17.99% decline from fiscal 2023.
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $562.36M, a 3.12% increase from fiscal 2022.
- Atea Pharmaceuticals, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $545.35M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $33.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $108.36M 10-Q · filed 2026-08-12 | $152.15M derived: sum of 3 quarters · filed 2026-08-12 | $166.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $74.55M 10-Q · filed 2026-05-12 | $118.34M derived: sum of 2 quarters · filed 2026-05-12 | $133.12M derived: sum of 3 quarters · filed 2026-05-12 | $233.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $43.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $58.57M derived: sum of 2 quarters · filed 2026-03-05 | $159.30M derived: sum of 3 quarters · filed 2026-08-12 | $281.94M 10-K · filed 2026-03-05 |
| 2025-09-30 | $14.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $115.51M derived: sum of 2 quarters · filed 2026-08-12 | $238.15M 10-Q · filed 2025-11-12 | $296.62M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $100.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $223.37M 10-Q · filed 2026-08-12 | $281.84M derived: sum of 3 quarters · filed 2026-08-12 | $510.08M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $122.64M 10-Q · filed 2026-05-12 | $181.11M derived: sum of 2 quarters · filed 2026-05-12 | $409.36M derived: sum of 3 quarters · filed 2026-05-12 | $416.62M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $58.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $286.72M derived: sum of 2 quarters · filed 2026-03-05 | $293.98M derived: sum of 3 quarters · filed 2026-03-05 | $461.18M 10-K · filed 2026-03-05 |
| 2024-09-30 | $228.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $235.51M derived: sum of 2 quarters · filed 2025-11-12 | $402.70M 10-Q · filed 2025-11-12 | $449.93M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $7.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $174.46M 10-Q · filed 2025-08-07 | $221.69M derived: sum of 3 quarters · filed 2025-08-07 | $426.98M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $167.20M 10-Q · filed 2025-05-12 | $214.43M derived: sum of 2 quarters · filed 2025-05-12 | $419.71M derived: sum of 3 quarters · filed 2025-05-12 | $572.93M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $47.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $252.52M derived: sum of 2 quarters · filed 2025-03-06 | $405.74M derived: sum of 3 quarters · filed 2025-03-06 | $562.36M 10-K · filed 2025-03-06 |
| 2023-09-30 | $205.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $358.51M derived: sum of 2 quarters · filed 2024-11-07 | $515.13M 10-Q · filed 2024-11-07 | $573.53M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $153.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $309.84M 10-Q · filed 2024-08-07 | $368.24M derived: sum of 3 quarters · filed 2024-08-07 | |
| 2023-03-31 | $156.63M 10-Q · filed 2024-05-14 | $215.02M derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $58.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $545.35M 10-K · filed 2024-02-28 | ||
| 2022-09-30 | $486.95M 10-Q · filed 2023-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |